Replies to post #402079 on Anavex Life Sciences Corp (AVXL)

[williamssc]

First off they need feedback from the FDA on whether another P3 is even needed and that meeting hasn't yet happened according to the last call. Missling just yesterday again released that their trial met both its co-primary and key secondary endpoints, showing statistically significant and clinically meaningful improvement in cognition and function as measured by ADAS-Cog, ADCS-ADL, and CDR-SB, respectively.